Is 4-Hydroxynonenal a Predictive Parameter for the Development of Joint Erosion in Patients With Rheumatoid Arthritis?

dc.contributor.authorAkgtol, Gurkan
dc.contributor.authorUlusoy, Hasan
dc.contributor.authorTelo, Selda
dc.contributor.authorGuslkesen, Arif
dc.contributor.authorYildirim, Tulay
dc.contributor.authorPoyraz, Ahmet Kursad
dc.contributor.authorKaya, Arzu
dc.date.accessioned2026-08-12T17:08:11Z
dc.date.issued2016
dc.departmentFırat Üniversitesi
dc.description.abstractObjectives: This study aims to evaluate serum 4-hydroxynonenal (4-HNE) levels and its clinical and radiological significance in patients with rheumatoid arthritis (RA). Patients and methods: The study included 40 patients (8 males, 32 females; mean age 51.4 +/- 11.2 years; range 24 to 72 years) with RA and 30 healthy controls (8 males, 32 females; mean age 53.0 +/- 11.7 years; range 24 to 72 years. Serum 4-HNE levels were measured using sandwich enzyme-linked immunosorbent assay method. Patients with disease activity score 28 <= 3.2 and >3.2 were allocated into low and high/moderate disease activity groups, respectively. Additionally, patients were divided into two groups as early RA (disease duration <= 2 years) and established RA (disease duration >= 2 years). Functional disability was evaluated using health assessment questionnaire. Radiographs were scored using the modified Larsen scoring. Results: Serum 4-HNE levels in patients with RA were significantly higher than controls (p=0.001). Serum 4-HNE levels did not correlate with laboratory or clinical parameters of disease activity including erythrocyte sedimentation rate, C-reactive protein, disease activity score 28, and health assessment questionnaire. Serum 4-HNE levels were higher in patients with established RA than patients with early RA (r=0.487, p=0.001). Besides, modified Larsen score which indicates structural damage correlated significantly with serum 4-HNE levels (p=0.001). Conclusion: These results indicate that serum 4-HNE levels may be used as an indicator for structural damage such as erosions in the early stage of RA; however, they are not efficient to monitor disease activity.
dc.identifier.doi10.5606/ArchRheumatol.2016.5945
dc.identifier.endpage81
dc.identifier.issn2148-5046
dc.identifier.issn1309-0283
dc.identifier.issue1
dc.identifier.orcid0000-0001-8992-1743
dc.identifier.orcid0000-0003-3655-0269
dc.identifier.pmid29900979
dc.identifier.startpage76
dc.identifier.trdizinid203318
dc.identifier.urihttps://doi.org/10.5606/ArchRheumatol.2016.5945
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/203318
dc.identifier.urihttps://hdl.handle.net/11508/49955
dc.identifier.volume31
dc.identifier.wosWOS:000372922300011
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTurkish League Against Rheumatism
dc.relation.ispartofArchives of Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subject4-hydroxynonenal
dc.subjectdisease activity
dc.subjectmodified Larsen score
dc.subjectrheumatoid arthritis
dc.titleIs 4-Hydroxynonenal a Predictive Parameter for the Development of Joint Erosion in Patients With Rheumatoid Arthritis?
dc.typeArticle

Dosyalar